{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:26:27Z","timestamp":1790519187520,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 R21 AR065089\u201001"],"award-info":[{"award-number":["1 R21 AR065089\u201001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Interstitial lung disease (<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>) is a frequent complication of systemic sclerosis (<jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c) (scleroderma) and the leading cause of scleroderma\u2010related deaths. There exists an unmet need for a new drug therapy for <jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>\u2010complicated <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c. Substantial evidence supports an important role for thrombin in the pathogenesis of <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010associated <jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content> (hereafter <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>), and targeting thrombin with a direct thrombin inhibitor could prove to be a novel and effective treatment strategy. As a first step toward designing a clinical trial to test the efficacy of thrombin inhibition in <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>, we conducted this study to test the safety and tolerability of dabigatran in patients with <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective, single\u2010center, open\u2010label treatment trial with the direct thrombin inhibitor, dabigatran, in patients with <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>. Any patient with a history of gastrointestinal hemorrhage or gastric antral vascular ectasia was excluded. Blood monitoring was performed monthly, and patient\u2010reported outcomes, pulmonary function tests, and skin scores were obtained at baseline and at 3\u2010 and 6\u2010month visits. Bronchoscopy with bronchoalveolar lavage (<jats:styled-content style=\"fixed-case\">BAL<\/jats:styled-content>) was performed at baseline and at 6 months for measurement of lung thrombin activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 15 patients with <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>, 14 completed 6 months of treatment with dabigatran at 75 mg taken orally twice daily. Adverse events were uncommon and usually mild or unrelated to the study medication. No serious adverse event was observed. Dabigatran was well tolerated, and we observed no significant gastrointestinal, pulmonary, or other safety issues or intolerability. <jats:styled-content style=\"fixed-case\">BAL<\/jats:styled-content> fluid thrombin activity decreased or remained stable in 13 of 14 (92.8%) subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dabigatran appears to be safe and well tolerated in patients with <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>c\u2010<jats:styled-content style=\"fixed-case\">ILD<\/jats:styled-content>. A larger randomized controlled trial to test the efficacy of direct thrombin inhibition with dabigatran can be considered.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11049","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T03:39:28Z","timestamp":1565062768000},"page":"403-411","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety and Tolerability of Thrombin Inhibition in Scleroderma\u2010Associated Interstitial Lung Disease"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-3278","authenticated-orcid":false,"given":"R. M.","family":"Silver","sequence":"first","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Akter","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Atanelishvili","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Huggins","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kajdasz","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. B.","family":"Highland","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Nietert","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Bogatkevich","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000249"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-426FR"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.10.002"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86608"},{"key":"e_1_2_7_7_1","first-page":"A5794","article-title":"Direct thrombin inhibition with dabigatran alters the matrix\u2010induced, pro\u2010fibrotic phenotype of fibroblasts","volume":"197","author":"Lumpkin TB","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00448.2003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30255"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-009-0082-2"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0314OC"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201305-0845LE"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201307-1328LE"},{"issue":"2","key":"e_1_2_7_14_1","first-page":"S169","article-title":"Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups","volume":"141","author":"The BAL Cooperative Group Steering Committee","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.10.4.7510986"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0703"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20598"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24730"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177731118"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(89)80072-1"},{"key":"e_1_2_7_25_1","first-page":"733","article-title":"Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis","volume":"22","author":"Beon M","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.5.1234"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10531"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64582-8"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106441200"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24935"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3330121"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:10:21Z","timestamp":1759421421000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/acr2.11049"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11049","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"2019-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}